<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15097">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02089308</url>
  </required_header>
  <id_info>
    <org_study_id>V00116 TD 1 06</org_study_id>
    <secondary_id>2013-005290-47</secondary_id>
    <nct_id>NCT02089308</nct_id>
  </id_info>
  <brief_title>Nicotine Patch - Bioequivalence Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence of a new transdermal nicotine
      patch to that of a reference formulation following repeated applications
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>During the third application of each period,12 time points up to 24h after the application</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax)</measure>
    <time_frame>During the third application of each period,12 time points up to 24h after the application</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>During the third application of each period, 12 time points up to 24h after the application</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy Smokers</condition>
  <arm_group>
    <arm_group_label>Treatment-Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.
Treatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)
The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.
Treatment-sequence 2 : Period 1 (reference) + period 2 (test drug)
The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test treatment : V0116 transdermal patch</intervention_name>
    <arm_group_label>Treatment-Sequence 1</arm_group_label>
    <arm_group_label>Treatment-Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference treatment : Nicotine transdermal patch</intervention_name>
    <arm_group_label>Treatment-Sequence 1</arm_group_label>
    <arm_group_label>Treatment-Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject aged 18 to 45 years (inclusive)

          -  Current Smoker of &gt;or = 5 and &lt; or = to 15 cigarettes/day

          -  Fagerström score &lt; or =5 at selection

          -  Absence of any clinically significant abnormal findings at physical examination,
             vital sign, Electrocardiogram ECG, biological examinations in the investigator's
             opinion.

        Exclusion Criteria:

          -  Presence of any significant medical findings or significant history (in particular
             any cardio-vascular disease, severe renal or hepatic insufficiency, current gastric
             or duodenal ulcer) that may impact the safety, the interpretation of the results
             and/or the participation of the subject in the study according to the opinion of the
             investigator

          -  Any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable
             to interfere with use or safety assessment of a transdermal patch
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Fabre Médicament</last_name>
    <email>contact_essais_cliniques@pierre-fabre.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Gieres</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Tobacco Use Disorder</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Nervous System Agents</mesh_term>
    <mesh_term>Nicotine polacrilex</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
